These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 29949016)

  • 21. Brain Activation in Response to Low-Calorie Food Pictures: An Explorative Analysis of a Randomized Trial With Dapagliflozin and Exenatide.
    van Ruiten CC; Veltman DJ; Nieuwdorp M; IJzerman RG
    Front Endocrinol (Lausanne); 2022; 13():863592. PubMed ID: 35600575
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exenatide extended-release; clinical trials, patient preference, and economic considerations.
    Doggrell SA
    Patient Prefer Adherence; 2013; 7():35-45. PubMed ID: 23341736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increase in endogenous glucose production with SGLT2 inhibition is attenuated in individuals who underwent kidney transplantation and bilateral native nephrectomy.
    Daniele G; Solis-Herrera C; Dardano A; Mari A; Tura A; Giusti L; Kurumthodathu JJ; Campi B; Saba A; Bianchi AM; Tregnaghi C; Egidi MF; Abdul-Ghani M; DeFronzo R; Del Prato S
    Diabetologia; 2020 Nov; 63(11):2423-2433. PubMed ID: 32827269
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
    Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
    Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exenatide challenge in oral glucose tolerance test is insufficient for predictions of glucose metabolism and insulin secretion after sleeve gastrectomy (SG) in obese patients with type 2 diabetes: a pilot study to establish a preoperative model to estimate β-cell function following augmented glucagon-like peptide-1 secretion after SG.
    Nakamura Y; Horie I; Kanetaka K; Eguchi S; Nakamichi S; Hongo R; Takashima M; Kawakami A; Abiru N
    Endocr J; 2022 Dec; 69(12):1457-1465. PubMed ID: 35896344
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.
    DeFronzo RA; Okerson T; Viswanathan P; Guan X; Holcombe JH; MacConell L
    Curr Med Res Opin; 2008 Oct; 24(10):2943-52. PubMed ID: 18786299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years.
    Macconell L; Pencek R; Li Y; Maggs D; Porter L
    Diabetes Metab Syndr Obes; 2013; 6():31-41. PubMed ID: 23358123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exenatide once weekly improved 24-hour glucose control and reduced glycaemic variability in metformin-treated participants with type 2 diabetes: a randomized, placebo-controlled trial.
    Frías JP; Nakhle S; Ruggles JA; Zhuplatov S; Klein E; Zhou R; Strange P
    Diabetes Obes Metab; 2017 Jan; 19(1):40-48. PubMed ID: 27527911
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes.
    Gastaldelli A; Repetto E; Guja C; Hardy E; Han J; Jabbour SA; Ferrannini E
    Diabetes Obes Metab; 2020 Mar; 22(3):393-403. PubMed ID: 31692226
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exenatide once weekly combined with metformin reduced glycemic variability in type 2 diabetes by using flash glucose monitoring system.
    Li Y; Han MM; He Q; Liu ZA; Liang D; Hou JT; Zhang Y; Liu YF
    World J Diabetes; 2020 Dec; 11(12):654-665. PubMed ID: 33384771
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of oral L-carnitine supplementation on insulin sensitivity indices in response to glucose feeding in lean and overweight/obese males.
    Galloway SD; Craig TP; Cleland SJ
    Amino Acids; 2011 Jul; 41(2):507-15. PubMed ID: 20963457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control.
    Stenlid R; Cerenius SY; Wen Q; Aydin BK; Manell H; Chowdhury A; Kristinsson H; Ciba I; Gjessing ES; Mörwald K; Gomahr J; Heu V; Weghuber D; Forslund A; Bergsten P
    Front Endocrinol (Lausanne); 2023; 14():1293093. PubMed ID: 38027106
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hyperglucagonemia in youth is associated with high plasma free fatty acids, visceral adiposity, and impaired glucose tolerance.
    Manell H; Kristinsson H; Kullberg J; Ubhayasekera SJK; Mörwald K; Staaf J; Cadamuro J; Zsoldos F; Göpel S; Sargsyan E; Ahlström H; Bergquist J; Weghuber D; Forslund A; Bergsten P
    Pediatr Diabetes; 2019 Nov; 20(7):880-891. PubMed ID: 31271247
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo.
    Pontiroli AE; Pacchioni M; Piatti PM; Cassisa C; Camisasca R; Pozza G
    J Clin Endocrinol Metab; 1996 Oct; 81(10):3727-32. PubMed ID: 8855830
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exenatide has a pronounced effect on energy intake but not energy expenditure in non-diabetic subjects with obesity: A randomized, double-blind, placebo-controlled trial.
    Basolo A; Burkholder J; Osgood K; Graham A; Bundrick S; Frankl J; Piaggi P; Thearle MS; Krakoff J
    Metabolism; 2018 Aug; 85():116-125. PubMed ID: 29596853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of fasting state-/oral glucose tolerance test-derived measures of insulin release for the detection of genetically impaired β-cell function.
    Herzberg-Schäfer SA; Staiger H; Heni M; Ketterer C; Guthoff M; Kantartzis K; Machicao F; Stefan N; Häring HU; Fritsche A
    PLoS One; 2010 Dec; 5(12):e14194. PubMed ID: 21152029
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: A randomized controlled trial (CODEX).
    Siskind DJ; Russell AW; Gamble C; Winckel K; Mayfield K; Hollingworth S; Hickman I; Siskind V; Kisely S
    Diabetes Obes Metab; 2018 Apr; 20(4):1050-1055. PubMed ID: 29194917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glucagon Levels During Short-Term SGLT2 Inhibition Are Largely Regulated by Glucose Changes in Patients With Type 2 Diabetes.
    Lundkvist P; Pereira MJ; Kamble PG; Katsogiannos P; Langkilde AM; Esterline R; Johnsson E; Eriksson JW
    J Clin Endocrinol Metab; 2019 Jan; 104(1):193-201. PubMed ID: 30137410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States.
    Guillermin AL; Lloyd A; Best JH; DeYoung MB; Samyshkin Y; Gaebler JA
    J Med Econ; 2012; 15(4):654-63. PubMed ID: 22369345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial.
    Derosa G; Franzetti IG; Querci F; Carbone A; Ciccarelli L; Piccinni MN; Fogari E; Maffioli P
    Pharmacotherapy; 2013 Aug; 33(8):817-26. PubMed ID: 23744726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.